Cargando…

Effect of steroid treatment on the diagnostic yield of baseline (18)f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma

Aggressive B cell lymphoma often requires prompt steroid treatment, even before baseline (18)f-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and definitive treatment, to alleviate symptoms or prevent organ damage. Since lymphoma is a steroid-sensitive malignancy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Geiger, Karyn Revital, Pasvolsky, Oren, Berger, Tamar, Raanani, Pia, Shochat, Tzippy, Gurion, Ronit, Anati, Tamer, Groshar, David, Gafter-Gvili, Anat, Bernstine, Hanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474759/
https://www.ncbi.nlm.nih.gov/pubmed/36104603
http://dx.doi.org/10.1186/s13550-022-00924-9
_version_ 1784789764203872256
author Geiger, Karyn Revital
Pasvolsky, Oren
Berger, Tamar
Raanani, Pia
Shochat, Tzippy
Gurion, Ronit
Anati, Tamer
Groshar, David
Gafter-Gvili, Anat
Bernstine, Hanna
author_facet Geiger, Karyn Revital
Pasvolsky, Oren
Berger, Tamar
Raanani, Pia
Shochat, Tzippy
Gurion, Ronit
Anati, Tamer
Groshar, David
Gafter-Gvili, Anat
Bernstine, Hanna
author_sort Geiger, Karyn Revital
collection PubMed
description Aggressive B cell lymphoma often requires prompt steroid treatment, even before baseline (18)f-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and definitive treatment, to alleviate symptoms or prevent organ damage. Since lymphoma is a steroid-sensitive malignancy, there are concerns that steroids might affect the results of FDG PET/CT and decrease its diagnostic yield. The aim of the current study was to evaluate the effect of steroids administered before baseline PET/CT on the maximum standardized uptake value (SUVmax) and additional PET/CT parameters. Retrospective review of the database in a tertiary medical center yielded 178 patients newly diagnosed with aggressive B cell lymphoma between January 2017 and May 2020 who had an available baseline FDG PET/CT scan. The cohort was divided into patients who received steroids before PET/CT (n = 47) and those who did not (n = 131), and the groups were compared for SUVmax and additional PET/CT parameters. The steroid-treated group had a higher disease stage and lactate dehydrogenase level compared to the steroid-naïve group, with a trend toward a higher international prognostic index. There was no significant between-group difference in SUVmax (P = 0.61). This finding remained consistent across steroid treatment durations and dosage regimens. Further evaluation revealed a significantly larger mean tumor volume and a trend toward a higher tumor metabolic burden in the steroid-treated group, yet no between-group difference in SUV mean or other PET/CT parameters. In this retrospective analysis of patients with aggressive B cell lymphoma, steroid prophase prior to baseline PET/CT did not decrease the diagnostic yield of the scan. However, further studies are required to fully appreciate the impact of steroids on PET CT parameters.
format Online
Article
Text
id pubmed-9474759
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-94747592022-09-16 Effect of steroid treatment on the diagnostic yield of baseline (18)f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma Geiger, Karyn Revital Pasvolsky, Oren Berger, Tamar Raanani, Pia Shochat, Tzippy Gurion, Ronit Anati, Tamer Groshar, David Gafter-Gvili, Anat Bernstine, Hanna EJNMMI Res Original Research Aggressive B cell lymphoma often requires prompt steroid treatment, even before baseline (18)f-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and definitive treatment, to alleviate symptoms or prevent organ damage. Since lymphoma is a steroid-sensitive malignancy, there are concerns that steroids might affect the results of FDG PET/CT and decrease its diagnostic yield. The aim of the current study was to evaluate the effect of steroids administered before baseline PET/CT on the maximum standardized uptake value (SUVmax) and additional PET/CT parameters. Retrospective review of the database in a tertiary medical center yielded 178 patients newly diagnosed with aggressive B cell lymphoma between January 2017 and May 2020 who had an available baseline FDG PET/CT scan. The cohort was divided into patients who received steroids before PET/CT (n = 47) and those who did not (n = 131), and the groups were compared for SUVmax and additional PET/CT parameters. The steroid-treated group had a higher disease stage and lactate dehydrogenase level compared to the steroid-naïve group, with a trend toward a higher international prognostic index. There was no significant between-group difference in SUVmax (P = 0.61). This finding remained consistent across steroid treatment durations and dosage regimens. Further evaluation revealed a significantly larger mean tumor volume and a trend toward a higher tumor metabolic burden in the steroid-treated group, yet no between-group difference in SUV mean or other PET/CT parameters. In this retrospective analysis of patients with aggressive B cell lymphoma, steroid prophase prior to baseline PET/CT did not decrease the diagnostic yield of the scan. However, further studies are required to fully appreciate the impact of steroids on PET CT parameters. Springer Berlin Heidelberg 2022-09-14 /pmc/articles/PMC9474759/ /pubmed/36104603 http://dx.doi.org/10.1186/s13550-022-00924-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
Geiger, Karyn Revital
Pasvolsky, Oren
Berger, Tamar
Raanani, Pia
Shochat, Tzippy
Gurion, Ronit
Anati, Tamer
Groshar, David
Gafter-Gvili, Anat
Bernstine, Hanna
Effect of steroid treatment on the diagnostic yield of baseline (18)f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma
title Effect of steroid treatment on the diagnostic yield of baseline (18)f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma
title_full Effect of steroid treatment on the diagnostic yield of baseline (18)f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma
title_fullStr Effect of steroid treatment on the diagnostic yield of baseline (18)f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma
title_full_unstemmed Effect of steroid treatment on the diagnostic yield of baseline (18)f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma
title_short Effect of steroid treatment on the diagnostic yield of baseline (18)f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma
title_sort effect of steroid treatment on the diagnostic yield of baseline (18)f-fluorodeoxyglucose positron emission tomography in aggressive b cell lymphoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474759/
https://www.ncbi.nlm.nih.gov/pubmed/36104603
http://dx.doi.org/10.1186/s13550-022-00924-9
work_keys_str_mv AT geigerkarynrevital effectofsteroidtreatmentonthediagnosticyieldofbaseline18ffluorodeoxyglucosepositronemissiontomographyinaggressivebcelllymphoma
AT pasvolskyoren effectofsteroidtreatmentonthediagnosticyieldofbaseline18ffluorodeoxyglucosepositronemissiontomographyinaggressivebcelllymphoma
AT bergertamar effectofsteroidtreatmentonthediagnosticyieldofbaseline18ffluorodeoxyglucosepositronemissiontomographyinaggressivebcelllymphoma
AT raananipia effectofsteroidtreatmentonthediagnosticyieldofbaseline18ffluorodeoxyglucosepositronemissiontomographyinaggressivebcelllymphoma
AT shochattzippy effectofsteroidtreatmentonthediagnosticyieldofbaseline18ffluorodeoxyglucosepositronemissiontomographyinaggressivebcelllymphoma
AT gurionronit effectofsteroidtreatmentonthediagnosticyieldofbaseline18ffluorodeoxyglucosepositronemissiontomographyinaggressivebcelllymphoma
AT anatitamer effectofsteroidtreatmentonthediagnosticyieldofbaseline18ffluorodeoxyglucosepositronemissiontomographyinaggressivebcelllymphoma
AT groshardavid effectofsteroidtreatmentonthediagnosticyieldofbaseline18ffluorodeoxyglucosepositronemissiontomographyinaggressivebcelllymphoma
AT gaftergvilianat effectofsteroidtreatmentonthediagnosticyieldofbaseline18ffluorodeoxyglucosepositronemissiontomographyinaggressivebcelllymphoma
AT bernstinehanna effectofsteroidtreatmentonthediagnosticyieldofbaseline18ffluorodeoxyglucosepositronemissiontomographyinaggressivebcelllymphoma